Tumors of the Central Nervous System, Volume 2: Gliomas: Glioblastoma (Part 2)

Front Matter....Pages i-xxi
Introduction....Pages 1-7
Front Matter....Pages 9-9
Gliomagenesis: Advantages and Limitations of Biomarkers....Pages 11-24
Molecular Subtypes of Gliomas....Pages 25-29
Glioblastoma: Germline Mutation of TP53 ....Pages 31-38
Familial Gliomas: Role of TP53 Gene....Pages 39-45
The Role of IDH1 and IDH2 Mutations in Malignant Gliomas....Pages 47-52
Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations....Pages 53-62
Metabolic Differences in Different Regions of Glioma Samples....Pages 63-72
Glioblastoma Patients: Role of Methylated MGMT....Pages 73-79
Brain Tumor Angiogenesis and Glioma Grading: Role of Tumor Blood Volume and Permeability Estimates Using Perfusion CT....Pages 81-91
Vasculogenic Mimicry in Glioma....Pages 93-101
Newly Diagnosed Glioma: Diagnosis Using Positron Emission Tomography with Methionine and Fluorothymidine....Pages 103-112
Role of Diffusion Tensor Imaging in Differentiation of Glioblastomas from Solitary Brain Metastases....Pages 113-121
 131 I-TM-601 SPECT imaging of Human Glioma....Pages 123-130
Assessment of Biological Target Volume Using Positron Emission Tomography in High-Grade Glioma Patients....Pages 131-141
Skin Metastases of Glioblastoma....Pages 143-149
Front Matter....Pages 151-151
Diffuse Low-Grade Gliomas: What Does “Complete Resection” Mean?....Pages 153-161
Quantitative Approach of the Natural Course of Diffuse Low-Grade Gliomas....Pages 163-172
Impact of Extent of Resection on Outcomes in Patients with High-Grade Gliomas....Pages 173-179
Glioma Surgery: Intraoperative Low Field Magnetic Resonance Imaging....Pages 181-187
Front Matter....Pages 151-151
Low-Grade Gliomas: Intraoperative Electrical Stimulations....Pages 189-205
Malignant Gliomas: Present and Future Therapeutic Drugs....Pages 207-214
Recurrent Malignant Glioma Patients: Treatment with Conformal Radiotherapy and Systemic Therapy....Pages 215-227
Glioblastoma: Boron Neutron Capture Therapy....Pages 229-239
Glioblastoma: Anti-tumor Action of Cyclosporin A and Functionally Related Drugs....Pages 241-253
Glioblastoma Patients: Chemotherapy with Cisplatin, Temozolomide and Thalidomide....Pages 255-260
Glioblastoma: Role of Galectin-1 in Chemoresistance....Pages 261-267
Glioma-Initiating Cells: Interferon Treatment....Pages 269-276
Glioblastoma: Anti-tumor Action of Natural and Synthetic Cannabinoids....Pages 277-287
Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan....Pages 289-299
Monitoring Gliomas In Vivo Using Diffusion-Weighted MRI During Gene Therapy-Induced Apoptosis....Pages 301-311
High-Grade Gliomas: Dendritic Cell Therapy....Pages 313-333
Glioblastoma Multiforme: Use of Adenoviral Vectors....Pages 335-347
Fischer/F98 Glioma Model: Methodology....Pages 349-359
Cellular and Molecular Characterization of Anti-VEGF and IL-6 Therapy in Experimental Glioma....Pages 361-369
Adult Brainstem Gliomas: Diagnosis and Treatment....Pages 371-377
The Use of Low Molecular Weight Heparin in the Treatment and Prevention of Thromboembolic Disease in Glioma Patients....Pages 379-384
Front Matter....Pages 385-385
Brainstem Gliomas: An Overview....Pages 387-395
Tumor-Associated Epilepsy in Patients with Glioma....Pages 397-406
Brain Tumors Arising in the Setting of Chronic Epilepsy....Pages 407-416
Front Matter....Pages 385-385
Low-Grade Gliomas: Role of Relative Cerebral Blood Volume in Malignant Transformation....Pages 417-423
Angiocentric Glioma-Induced Seizures: Lesionectomy....Pages 425-434
Back Matter....Pages 435-458